Rossari Biotech Posts Highest-Ever Q1 FY27 Results; Revenue Jumps 28% YoY
Mumbai: Rossari Biotech Limited, a manufacturer of specialty chemicals providing sustainable solutions across various industries, announced its financial performance for the quarter ended June 30, 2026. The company achieved a highest-ever quarterly revenue of Rs. 697.2 crore and an EBITDA of Rs. 80.6 crore in consolidated terms.The results reflect robust growth across Rossari’s business segments, driven by momentum in the domestic market and expanding international presence, according to a joint statement from Promoter & Executive Chairman Mr. Edward Menezes and Promoter & Managing Director Mr. Sunil Chari.
Consolidated Q1 FY27 Performance Overview
Rossari Biotech reported significant consolidated growth compared to Q1 FY26. The key performance indicators for the quarter are detailed below:| Metric | Q1 FY27 (Rs.) | Change YoY | Q1 FY26 (Rs.) |
|---|---|---|---|
| Revenue from Operations | 697.2 crore | Up 28% | 543.7 crore |
| EBITDA | 80.6 crore | Up 19% | 67.9 crore |
| PAT | 35.1 crore | Up 4% | 33.6 crore |
| EPS (Diluted) | Rs. 6.3 | - | Rs. 6.1 |
Standalone Financial Snapshot
On a standalone basis, the company also demonstrated strong growth in Q1 FY27. Revenue from operations rose by 32%, while profitability metrics showed healthy improvement.| Metric | Q1 FY27 (Rs.) | Change YoY | Q1 FY26 (Rs.) |
|---|---|---|---|
| Revenue from Operations | 482.3 crore | Up 32% | 365.8 crore |
| EBITDA | 56.4 crore | Up 28% | 43.9 crore |
| PAT | 34.3 crore | Up 31% | 26.2 crore |
| EPS (Diluted) | Rs. 6.2 | - | Rs. 5.8 |
Strategic Milestones and Developments
The company highlighted several key strategic developments during the quarter, strengthening its global footprint and focusing on efficiency:- Southeast Asia Expansion: Rossari established a greenfield blending facility in Thailand through its subsidiary, Unistar Thai. This facility boasts an installed capacity of 5,000 MTPA across powders, granules, and liquids and is designed to offer customized formulations aligned with local market needs.
- Asset Monetization: The company progressed in the monetization of non-core assets, completing the sale of its Andheri office during Q1 FY27, following a prior sale of the Kanjurmarg office.
Mr. Menezes and Mr. Chari stated that the performance reflects disciplined execution and diversification across their business segments, including Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC), and Animal Health and Nutrition (AHN). They noted that international business continued steady progress, supported by growing acceptance of specialty solutions in overseas markets.
The management reaffirmed its focus on continuous innovation and profitable growth throughout FY27. Supported by a strong balance sheet and integrated manufacturing platform, the company aims to capitalize on emerging opportunities and create sustainable long-term value for stakeholders.
ROSSARI Stock Price Movement
Shares of Rossari Biotech Limited slipped by 1.30%, closing at ₹531.45 on Friday after shedding ₹7.05 from the previous close. The stock traded amidst a daily range, completing its session on a volume of 72,267 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.